Oral anticoagulation for prolonging survival in patients with cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Akl, Elie A ^a   Kamath, G ^b   Kim, S Y ^b   Yosuico, V ^b   Barba, M ^b   Terrenato, I ^b   Sperati, F ^b   Schunemann H J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

Administration, oral; Anticoagulants *administration dosage; adverse effects ; Carcinoma, small cell mortality ; Hemorrhage chemically induced ; Lung neoplasms mortality ; Neoplasms *mortality ; Randomized controlled trials as topic

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; PLACEBO; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DATA BASE; DATA EXTRACTION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LEUKEMIA; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MEDLINE; MORTALITY; MULTIPLE CYCLE TREATMENT; NEOPLASM; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 42949084376     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006466     Document Type: Review

References (60)

1. Chahinian 1989 {published data only} Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in Extensive small-cell lung cancer by the Cancer and Leukemia Group B. Journal of Clinical Oncology 1989;7(8):993-1002.
2. Daly 1991 {published data only} Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clinical & Experimental Metastasis 1991;9(1):3-11.
3. Levine 1994 {published data only} Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343(8902):886-9.
4. Maurer 1997 {published data only} Maurer LH, Herndon IJ, Hollis DR, Aisner J, Carey RW, Skarin AT, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 1997;15(11):3378-87.
5. Zacharski 1981 {published data only} Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans administration study No. 75. 1981 JAMA;245(8):831-35.
6. Zacharski 1984 {published data only} Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984;53(10):2046-52.
7. Aisner 1987 Aisner J, Propert K. Aggressive combination chemotherapy, chest and brain irradiation and warfarin for the treatment of limited disease of small cell lung cancer (SCLC). Proceedings of the American Society of Clininical Oncology 1987;6:179.
8. Aisner 1992 Aisner J, Goutsou M, Maurer LH, Cooper R, Chahinian P, Carey R, et al. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: A Cancer and Leukemia Group B pilot study. Journal of Clinical Oncology 1992;10(8):1230-36.
9. Anonymous 1994 Anonymous. Coumarin (1,2-benzopyrone) -New findings for tumor therapy. Medizinische Welt 1994;45(5):62-3.
10. Carpi 1995 Carpi A, Sagripanti A, Poddighe R, Gherarducci G, Nicolini A. Cancer incidence and mortality in patients with heart disease. Effect of oral anticoagulant therapy. American Journal of Clinical Oncology 1995;18(1):15-8.
11. Chahinian 1984 Chahinian AP, Ware JH, Zimmer B, Comis RL, Perry MC, Hirsh V, et al. Evaluation of anticoagulation with warfarin and of alternating chemotherapy in Extensive small-cell lung cancer (SCCL). Proceedings of the American Society of Clininical Oncology 1984;abstract:C-879.
12. Chahinian 1985 Chahinian AP, Ware JH, Zimmer B, Comis RL, Perry MC, Hirsh V, et al. Update on anticoagulation with warfarin and of alternating chemotherapy in Extensive small-cell lung cancer (SCCL). Proceedings of the American Society of Clininical Oncology 1985;4:191.
13. Chlebowski 1982 Chlebowski RT, Gota CH, Chan KK, Weiner JM, Block JB, Bateman JR. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Research 1982;42(11):4827-30.
14. D'Souza 1980a D'Souza DP, Daly L, Thornes RD. Low dosage chemoimmunotherapy plus warfarin in metastatic breast cancer. Irish Journal of Medical Science 1980;149(4):172-3.
15. D'Souza 1980b D'Souza DP, Daly L, Thornes RD. Cyclophosphamide, prednisone, staphage lysate and warfarin in disseminated breast cancer. Irish Medical Journal 1980;73(10):385-7.
16. Herrmann 1988 Herrmann, R. Coumarin and cimetidine in the treatment of metastatic renal cell carcinoma. Proceedings of the American Society of Clininical Oncology 1988;7:131.
17. Herrmann 1990 Herrmann R, Manegold C, Maurer B, Hennig FW, Matthiessen W. Phase II trial of coumarin and cimetidine in advanced renal cell carcinoma. Annals of Oncology 1990;1(6):445-6.
18. Higashi 1971 Higashi H, Heidelberger C. Lack of effect of warfarin (NSC-59813) alone or in combination with 5-fluorouracil (NSC-19893) on primary and metastatic L1210 leukemia and adenocarcinoma 755. Cancer Chemotherapy Reports - Part 1 1971;55(1):29-33.
19. Huber 1993 Huber MH, Hong WK. Warfarin and small-cell lung cancer. Journal of Clinical Oncology 1993;11(2):383.
20. Hutchins 1984 Hutchins LF, Cash DK, Lang NP, Neilan BA. Coumarin And Cimetidine As Active Agents In Melanoma And Renal-Cell Carcinoma. Clinical Research 1984;32(5):A873.
21. Kokron 1990 Kokron O, Baumgartner G, Theyer G. Maca S, Gasser G, Schmidt PR, et al. Cimetidine and coumarin treatment of metastatic renal cell carcinoma. Journal of Cancer Research & Clinical Oncology 1990;116(Suppl):971.
22. Kokron 1993 Kokron O, Baumgartner G, Theyer G, Maca S, Gasser G, Schmidt PR, et al. Randomised study in metastatic renal cell cancer: Coumarin versus coumarin and cimetidine. Journal of the Irish Colleges of Physicians & Surgeons 1993;22(SUPPL 1):10-11.
23. Lebeau 1993 Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C. No Effect Of An Antiaggregant Treatment With Aspirin In Small-Cell Lung-Cancer Treated With Ccavp16 Chemotherapy - Results From A Randomized Clinical-Trial Of 303 Patients. Cancer 1993;71(5):1741-5.
24. Lecumberri 2005 Lecumberri R, Paramo JA, Rocha E. Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica-The Hematology Journal 2005;90(9):1258-66.
25. Macareo 2001 Macareo LR, Ford SM, Crocker JD, Coleman TA. Low dose warfarin decreases central line thrombosis and tissue plasminogen activator (TPA) utilization in cancer patients but does not inprove overall survival. Blood 2001;98(11):94B-95B.
26. Marshall 1987 Marshall ME, Mendelsohn L, Butler K, Cantrell J, Harvey J, Macdonald J. Treatment of non-small cell lung cancer with coumarin and cimetidine. Cancer Treatment Reports 1987;71(1):91-2.
27. Marshall 1989 Marshall ME, Butler K, Cantrell J, Wiseman C, Mendelsohn L. Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study. Cancer Chemotherapy & Pharmacology 1989;24(1):65-6.
28. Marshall 1990 Marshall FF. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma: Editorial comment. Journal of Urology 1990;144(5):1317.
29. McCulloch 1987 McCulloch P, George WD. Warfarin inhibition of metastasis: the role of anticoagulation. British Journal of Surgery 1987;74(10):879-83.
30. Moazzam 2003 Moazzam N, Potti A. Survival and outcome data in patients with adenocarcinoma of the prostate receiving warfarin therapy. Blood 2003;102(11):325A.
31. Mohler 1993 Mohler JL, Williams B, Thompson I, Marshall ME. Coumarin (1, 2-benzopyrone) for the treatment of prostatic carcinoma. Journal of the Irish Colleges of Physicians & Surgeons 1993;22(Suppl 1):12-16.
32. Mohler 1994 Mohler JL, Williams BT, Thompson IM, Marshall ME. Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma. Journal of Cancer Research & Clinical Oncology 1994;120(Supplement):S35- S38.
33. Sagaster 1995 Sagaster P, Micksche M, Flamm J, Ludwig H Sagaster P, Micksche M, et al. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Annals of Oncology : official journal of the European Society for Medical Oncology 1995;6(10):999-1003.
34. Smorenburg 2001a Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacological Review 2001;53(1):93-105.
35. Taliani 2003 Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. Journal Of Thrombosis and Haemostasis 2003;1(8):1730-33.
36. Taliani 2004 Taliani MR, Agnelli G, Prandoni P. Vitamin K antagonists and cancer: reply to rebuttal. Journal Of Thrombosis and Haemostasis 2004;2(2):378-9.
37. Thornes 1972 Thornes RD. Warfarin as maintenance therapy for cancer. Journal of the Irish Colleges of Physicians and Surgeons 1972;29(2):41-2.
38. Thornes 1974 Thornes RD. Oral anticoagulant therapy of human cancer. Journal of Medicine 1974;5(1):83-91.
39. Thornes 1975 Thornes RD. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer 1975;35(1):91-7.
40. Thornes 1984 Thornes RD. Prevention Of Recurrence Of Kaposis Sarcoma, Breast-Cancer And Melanoma By Coumarin. Irish Journal Of Medical Science 1984;153(5):187.
41. Thornes 1989 Thornes D, Daly L, Lynch G, Browne H, Tanner A, Keane, et al. Prevention of early recurrence of high risk malignant melanoma by coumarin. European Journal of Surgical Oncology 1989;15(5):431-5.
42. Thornes 1993 Thornes RD. Prevention of recurrence of malignant melanoma by coumarin (1,2-benzopyrone). Journal of the Irish Colleges of Physicians & Surgeons 1993;22(SUPPL 1):17-9.
43. Thornes 1994 Thornes RD, Daly L, Lynch G, Breslin B, Browne H, Browne HY, et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. Journal of Cancer Research & Clinical Oncology 1994;120(Suppl):S32-4.
44. Tiska-Rudman 2001 Tiska-Rudman L, Stamenic V, Rudman Jr F, Zekaj S, Sabol R. Ten-year survival in patients receiving anticoagulant therapy for breast cancer. Libri Oncologici 2001;29(2):99-108.
45. Venook 1989 Venook AP, Davenport Y, Tseng A, Jr. Activity of coumarin and cimetidine in metastatic renal cell carcinoma. Journal of Clinical Oncology 1989;7(3):402-3.
46. Zacharski 1979 Zacharski LR. Clinical trial of warfarin in cancer. Thrombosis & Haemostasis 1979;42(1).
47. Zacharski 1982a Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, et al. Effect Of Warfarin Therapy On Survival In Cancer - Final Report Of VA Cooperative Study #75. Circulation 1982;66(4):302.
48. Zacharski 1982b Zacharski LR. Warfarin and cancer. Annals of Internal Medicine 1982;97(5):784.
49. Zacharski 1990 Zacharski LR, Henderson WG. Warfarin for small-cell lung cancer: why not?. Journal of Clinical Oncology 1990;8(7): 1282-3.
50. Zacharski 1993 Zacharski LR. Warfarin therapy for cancer. Journal of the Irish Colleges of Physicians & Surgeons 1993;22(Suppl 1):20-3.
51. Zacharski 2002 Zacharski LR, Henderson WG. A rebuttal: vitamin K antagonists and cancer survival. Thrombosis & Haemostasis 2002;88(1):173-75.
52. Dvorak 1986 Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 1986;315(26):1650-9.
53. Francis 1998 Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Seminars in Thrombosis & Hemostasis 1998;24(2):93-109.
54. Haynes 2002 Haynes RB, Devereaux PJ, Guyatt GH. Clinical Expertise in the era of evidence based medicine and patient choice. ACP Journal Club 2002;136:A 11.
55. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1593-1598.
56. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
57. Levine 2003 Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. Journal of Thrombosis & Haemostasis 2003;1(7):1456-63.
58. Miller 2004 Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. Journal of Thrombosis & Haemostasis 2004;2(12):2107-14.
59. Schulman 2000 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. New England Journal of Medicine 2000;342(26):1953-8.
60. Smorenburg 2001b Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thrombosis & Haemostasis 2001;86(6):1586-7.